Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

3
(from Reference Citation Analysis)

Article PDFs (1)

Cited by > 0 (3)

Searched Name

Steven Fokkenrood

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number

Citation Analysis

Bydlon TM, Torjesen A, Fokkenrood S, Di Tullio A, Flexman ML. 3D Visualisation of Navigation Catheters for Endovascular Procedures Using a 3D Hub and Fiber Optic RealShape Technology: Phantom Study Results. EJVES Vasc Forum 2023;59:24-30. [PMID: 37389371 PMCID: PMC10300314 DOI: 10.1016/j.ejvsvf.2023.05.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 02/23/2023] [Accepted: 05/09/2023] [Indexed: 07/01/2023] Open

Abstract

Objective

Fiber Optic RealShape (FORS) is a new technology that visualises the full three dimensional (3D) shape of guidewires using an optical fibre embedded in the device. Co-registering FORS guidewires with anatomical images, such as a digital subtraction angiography (DSA), provides anatomical context for navigating these devices during endovascular procedures. The objective of this study was to demonstrate the feasibility and usability of visualising compatible conventional navigation catheters, together with the FORS guidewire, in phantom with a new 3D Hub technology and to understand potential clinical benefits.

Methods

The accuracy of localising the 3D Hub and catheter in relation to the FORS guidewire, was evaluated using a translation stage test setup and a retrospective analysis of prior clinical data. Catheter visualisation accuracy and navigation success was assessed in a phantom study where 15 interventionists navigated devices to three pre-defined targets in an abdominal aortic phantom using an Xray or computed tomography angiography (CTA) roadmap. Additionally, the interventionists were surveyed about the usability and potential benefits of the 3D Hub.

Results

The location of the 3D Hub and catheter along the FORS guidewire was detected correctly 96.59% of the time. During the phantom study, all 15 interventionists successfully reached the target locations 100% of the time and the error in catheter visualisation was 0.69 mm. The interventionists agreed or strongly agreed that the 3D Hub was easy to use and the greatest potential clinical benefit over FORS is in offering interventionists choice over which catheter they used.

Conclusion

This set of studies has shown that FORS guided catheter visualisation, enabled by a 3D Hub, is accurate and easy to use in a phantom setting. Further evaluation is needed to understand the benefits and limitations of the 3D Hub technology during endovascular procedures.

Collapse

Haines DE, Wright M, Harks E, Deladi S, Fokkenrood S, Brink R, Belt H, Kolen AF, Mihajlovic N, Zuo F, Rankin D, Stoffregen W, Cockayne D, Cefalu J. Near-Field Ultrasound Imaging During Radiofrequency Catheter Ablation. Circ Arrhythm Electrophysiol 2017;10:CIRCEP.117.005295. [DOI: 10.1161/circep.117.005295] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Accepted: 10/11/2017] [Indexed: 11/16/2022]

Affiliation(s)

David E. Haines From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Matthew Wright From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Erik Harks From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Szabolcs Deladi From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Steven Fokkenrood From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Rob Brink From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Harm Belt From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Alexander F. Kolen From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Nenad Mihajlovic From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Fei Zuo From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Darrell Rankin From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
William Stoffregen From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Debra Cockayne From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)
Joseph Cefalu From the Department of Cardiovascular Medicine, Beaumont Health System and Oakland University William Beaumont School of Medicine, Royal Oak, MI (D.E.H.,); St. Thomas’ Hospital, London, United Kingdom (M.W.); Philips Healthcare, Best, The Netherlands (E.H., S.D., S.F., R.B.); Philips Research, Eindhoven, The Netherlands (H.B., A.F.K., N.M., F.Z.); and Boston Scientific Co. Inc, San Jose, CA (D.R., W.S., D.C., J.C.)

Collapse

Wright M, Harks E, Deladi S, Suijver F, Barley M, van Dusschoten A, Fokkenrood S, Zuo F, Sacher F, Hocini M, Haïssaguerre M, Jaïs P. Real-time lesion assessment using a novel combined ultrasound and radiofrequency ablation catheter. Heart Rhythm 2011;8:304-12. [PMID: 21044698 DOI: 10.1016/j.hrthm.2010.10.039] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2010] [Accepted: 10/27/2010] [Indexed: 11/27/2022]